Dyadic International, Inc. (DYAI)

US — Healthcare Sector
Peers: HOWL  EWTX  DBTX  CELC  CCCC  ANEB  PMVP  ANTX  ELYM  HCWB  MOLN  MNOV  CSBR  CYT  FBRX  DMAC  KA  KTRA 

Automate Your Wheel Strategy on DYAI

With Tiblio's Option Bot, you can configure your own wheel strategy including DYAI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DYAI
  • Rev/Share 0.1189
  • Book/Share 0.0309
  • PB 30.3523
  • Debt/Equity 5.4839
  • CurrentRatio 3.9779
  • ROIC -0.972

 

  • MktCap 28225077.0
  • FreeCF/Share -0.161
  • PFCF -5.8661
  • PE -4.8109
  • Debt/Assets 0.6416
  • DivYield 0
  • ROE -2.3369

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
DYAI
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutrition, and industrial markets.

Read More
image for news Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
DYAI
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025.

Read More
image for news Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Dyadic to Present at World Vaccine Congress | Washington
DYAI
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C.

Read More
image for news Dyadic to Present at World Vaccine Congress | Washington
Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript
DYAI
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Neutral

Dyadic International, Inc. (NASDAQ:DYAI ) Q4 2024 Earnings Conference Call March 26, 2025 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Joe Hazelton - Chief Operating Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Vernon Bernardino - HC Wainwright Dick Williams - Williams Resource Group Operator Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode.

Read More
image for news Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript

About Dyadic International, Inc. (DYAI)

  • IPO Date 2008-01-16
  • Website https://www.dyadic.com
  • Industry Biotechnology
  • CEO Mr. Mark A. Emalfarb
  • Employees 6
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.